Amisulpride

(Barhemsys®)

Barhemsys®

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormInjection (intravenous; 5 mg/2 mL [2.5 mg/mL], 10 mg/4 mL [2.5 mg/mL])
Drug ClassDopamine-2 antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in adults for prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class.
  • Indicated in adults for treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Amisulpride (Barhemsys) is an effective D₂/D₃ antagonist for both prevention and treatment of postoperative nausea and vomiting (PONV), providing a significant improvement in the incidence of complete response compared to placebo.
  • Six systematic reviews/meta-analyses focused on Barhemsys's comparative efficacy and safety profile against other antiemetics such as aprepitant, ramosetron, granisetron, dexamethasone, and ondansetron.
  • The majority of studies involved women (83%) with a mean age of participants being 42 years; this suggests that most data available may have a potential bias towards females and primarily concerns middle-aged adults.
  • In terms of overall ranking against other antiemetics for reducing vomiting, drugs like aprepitant lead the efficacy rankings while amisulpride, along with granisetron, are noted for having little or no increase in any adverse events compared to placebo.
  • Among specific adverse events associated with amisulpride use for PONV treatment or prevention, minimal liability was observed; it had similar rates to those seen with placebos, indicating its relative safety.
  • While some antiemetics like aprepitant may show higher effectiveness in certain metrics than Barhemsys (amisulpride), it maintains a competitive position, especially in scenarios requiring rescue treatment after the failure of prophylaxis due to its commendable safety profile.